BR112022025763A2 - Aptâmeros para aplicações de cuidados com a saúde pessoal - Google Patents

Aptâmeros para aplicações de cuidados com a saúde pessoal

Info

Publication number
BR112022025763A2
BR112022025763A2 BR112022025763A BR112022025763A BR112022025763A2 BR 112022025763 A2 BR112022025763 A2 BR 112022025763A2 BR 112022025763 A BR112022025763 A BR 112022025763A BR 112022025763 A BR112022025763 A BR 112022025763A BR 112022025763 A2 BR112022025763 A2 BR 112022025763A2
Authority
BR
Brazil
Prior art keywords
icam
aptameres
adhesion molecule
intercellular adhesion
healthcare applications
Prior art date
Application number
BR112022025763A
Other languages
English (en)
Inventor
Esteban Velasquez Juan
Christopher Rupard Spencer
Violet Trejo Amy
Michael Pitz Adam
Lee Schmeichel Kelly
Nicole Swigart Erin
Allen Penner Gregory
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR112022025763A2 publication Critical patent/BR112022025763A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

APTÂMEROS PARA APLICAÇÕES DE CUIDADOS COM A SAÚDE PESSOAL. É revelada uma composição de aptâmero que possui um ou mais oligonucleotídeos que incluem ao menos um entre desoxirribonucleotídeos, ribonucleotídeos, derivados de desoxirribonucleotídeos, derivados de ribonucleotídeos, ou misturas dos mesmos. A composição de aptâmero tem uma afinidade de ligação a uma ou mais glicoproteínas de membrana celular selecionadas do grupo que consiste em: molécula de adesão intercelular 1 (ICAM-1), membros da família do receptor de lipoproteína de baixa densidade (LDLR) e membro 3 da família relacionada à caderina 3 (CDHR3), de preferência a molécula de adesão intercelular 1 (ICAM-1), e é configurada para reduzir a ligação de um ou mais rinovírus humanos à molécula de adesão intercelular 1 (ICAM-1).
BR112022025763A 2020-06-25 2021-06-24 Aptâmeros para aplicações de cuidados com a saúde pessoal BR112022025763A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043952P 2020-06-25 2020-06-25
PCT/US2021/038785 WO2021262911A1 (en) 2020-06-25 2021-06-24 Aptamers for personal health care applications

Publications (1)

Publication Number Publication Date
BR112022025763A2 true BR112022025763A2 (pt) 2023-01-10

Family

ID=76943162

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025763A BR112022025763A2 (pt) 2020-06-25 2021-06-24 Aptâmeros para aplicações de cuidados com a saúde pessoal

Country Status (8)

Country Link
US (1) US11859187B2 (pt)
EP (1) EP4172337A1 (pt)
CN (1) CN115996729A (pt)
AU (1) AU2021296450A1 (pt)
BR (1) BR112022025763A2 (pt)
CA (1) CA3176605A1 (pt)
MX (1) MX2022016049A (pt)
WO (1) WO2021262911A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114802A1 (en) * 2021-12-14 2023-06-22 The Procter & Gamble Company Aptamers for personal health care applications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
JP2007532662A (ja) 2004-04-13 2007-11-15 （オーエスアイ）アイテツク・インコーポレーテツド 高分子量の立体的な基へ抱合された核酸アプタマー
US8778307B2 (en) 2009-06-05 2014-07-15 University Of Maryland, College Park Targeted carriers for drug delivery across the gastrointestinal epithelium
WO2010141879A2 (en) 2009-06-05 2010-12-09 University Of Maryland College Park Peptides for transport of therapeutics and their carriers in mouse models and humans
US20130209514A1 (en) 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
BR112015009138A2 (pt) 2012-10-23 2020-10-20 Caris Life Sciences Switzerland Holdings, S.A.R.L. métodos para caracterizar um câncer
EP3039174B1 (en) 2013-08-28 2019-10-16 Caris Science, Inc. Oligonucleotide probes and uses thereof
JP2018526030A (ja) 2015-09-04 2018-09-13 ネオベンチャーズ バイオテクノロジー インコーポレイテッド 結合していない標的についてのアプタマーの選抜のための方法
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
WO2020020947A1 (en) * 2018-07-26 2020-01-30 Bracco Imaging Spa Icam-1 aptamers, diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
CN115996729A (zh) 2023-04-21
MX2022016049A (es) 2023-02-09
US20210403919A1 (en) 2021-12-30
WO2021262911A1 (en) 2021-12-30
AU2021296450A1 (en) 2022-10-20
EP4172337A1 (en) 2023-05-03
CA3176605A1 (en) 2021-12-30
US11859187B2 (en) 2024-01-02

Similar Documents

Publication Publication Date Title
Kennedy et al. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-mediated production of reactive oxygen species is an essential step in the mechanism of action to accelerate human keratinocyte differentiation
Baxter et al. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system
Mao et al. Neuroprotection by dehydroepiandrosteronesulfate: role of an NFκB-like factor
Fazio et al. Stimulation of suicidal erythrocyte death by garcinol
BR112022025763A2 (pt) Aptâmeros para aplicações de cuidados com a saúde pessoal
Formisano et al. MS-275 inhibits aroclor 1254–induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter
Pellacani et al. Evaluation of DNA damage induced by 2 polybrominated diphenyl ether flame retardants (BDE-47 and BDE-209) in SK-N-MC cells
Dock et al. DNA methylation inhibitor zebularine confers stroke protection in ischemic rats
BRPI0518011A (pt) uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro
Fiorillo et al. Estrogen receptor, inflammatory, and FOXO transcription factors regulate expression of myasthenia gravis-associated circulating microRNAs
Zhang et al. Equine estrogens differentially inhibit DNA fragmentation induced by glutamate in neuronal cells by modulation of regulatory proteins involved in programmed cell death
Ishibashi et al. Estrogenic effects of fluorotelomer alcohols for human estrogen receptor isoforms α and β in vitro
Mendell et al. Neurosteroid metabolites of testosterone and progesterone differentially inhibit ERK phosphorylation induced by amyloid β in SH-SY5Y cells and primary cortical neurons
Serrano-Nascimento et al. Excess iodide downregulates Na+/I− symporter gene transcription through activation of PI3K/Akt pathway
Vasko et al. Telomerase gene expression bioassays indicate metabolic activation of genotoxic lower chlorinated polychlorinated biphenyls
Hansen‐Schwartz et al. Protein kinase mediated upregulation of endothelin A, endothelin B and 5‐hydroxytryptamine 1B/1D receptors during organ culture in rat basilar artery
Bi et al. Identification of known drugs targeting the endoplasmic reticulum stress response
Fernández et al. Age and sex differences in self-esteem among Spanish adolescents
Kundakovic Sex-specific epigenetics: implications for environmental studies of brain and behavior
Tan et al. Coexpression with auxiliary β subunits modulates the action of tefluthrin on rat Nav1. 6 and Nav1. 3 sodium channels
Adefolaju et al. BAX/BCL-2 mRNA and protein expression in human breast MCF-7 cells exposed to drug vehicles-methanol and dimethyl sulfoxide (DMSO) for 24 hrs
Bueno-Nava et al. The Selective Inhibition of the D 1 Dopamine Receptor Results in an Increase of Metabolized Dopamine in the Rat Striatum
Sawyer et al. Comparative toxicity of mono-and bifunctional alkylating homologues of sulphur mustard in human skin keratinocytes
Obara-Michlewska et al. Ammonia upregulates kynurenine aminotransferase II mRNA expression in rat brain: a role for astrocytic NMDA receptors?
Soukup et al. Influence of testosterone on phase II metabolism and availability of soy isoflavones in male Wistar rats